Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | TARS1 | P26639 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037173 | 1.00 | ADORA1 (0.38) | ADORA1TARS1ADORA3SLC29A1ADORA2A | |
| SCHEMBL30674291 | 0.90 | TARS1 (0.37) | ADORA1TARS1ADORA3SLC29A1ADORA2A | |
| SCHEMBL21274225 | 0.90 | TARS1 (0.37) | ADORA1TARS1ADORA3SLC29A1ADORA2A | |
| SCHEMBL2056703 | 0.88 | ADORA1 (0.39) | ADORA1ADORA3SLC29A1 | |
| SCHEMBL17371759 | 0.88 | TARS1 (0.37) | ADORA1TARS1SLC29A1 | |
| SCHEMBL30379388 | 0.85 | ADORA3 (0.37) | ADORA1ADORA3SLC29A1ADORA2A | |
| SCHEMBL29089525 | 0.83 | TARS1 (0.39) | ADORA1TARS1SLC29A1 | |
| SCHEMBL16987222 | 0.81 | TARS1 (0.38) | ADORA1TARS1SLC29A1 | |
| SCHEMBL28564130 | 0.81 | TARS1 (0.38) | ADORA1TARS1SLC29A1 | |
| SCHEMBL29435121 | 0.81 | TARS1 (0.38) | ADORA1TARS1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139294-A1 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION | UNIV TEMPLE (US) | 2024-05-02 | — | — | US | disclosed |
| US-11939363-B2 | Translatable molecules and synthesis thereof | ARCTURUS THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939600-B2 | Compositions and methods for treating phenylketonuria | ARCTURUS THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240078661-A1 | RNA MOLECULES, METHODS OF PRODUCING CIRCULAR RNA, AND TREATMENT METHODS | UNIV CORNELL (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240058368-A1 | Respirable Polynucleotide Powder Formulations for Inhalation | MERZ PHARMACEUTICALS, LLC | 2024-02-22 | — | — | US | disclosed |
| WO-2024008189-A1 | METHODS AND SYSTEMS FOR PURIFYING CIRCULAR NUCLEIC ACIDS | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-01-11 | — | — | WO | disclosed |
| US-20240002815-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4299750-A2 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | Arcturus Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230398076-A1 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | ARCTURUS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023231959-A2 | SYNTHETIC CIRCULAR RNA COMPOSITIONS AND METHODS OF USE THEREOF | SHANGHAI CIRCODE BIOMED CO., LTD (CN) | 2023-12-07 | — | — | WO | disclosed |
| WO-2018222890-A1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018213789-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | MODERNATX, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180327471-A1 | TRANSLATABLE MOLECULES AND SYNTHESIS THEREOF | ARCTURUS THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180195077-A1 | METHODS OF ENHANCING TRANSLATION ABILITY OF RNA MOLECULES, TREATMENTS, AND KITS | CORNELL UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160060622-A1 | METHODS AND KIT FOR CHARACTERIZING THE MODIFIED BASE STATUS OF A TRANSCRIPTOME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-03 | — | — | US | disclosed |
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | disclosed |
| US-20110143397-A1 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| EP-1944321-A2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | North Carolina State University (US) | 2008-07-16 | — | — | EP | disclosed |
| US-6727059-B1 | ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398076-A1 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | AUP1, RNGTT, LIPC | ADORA1 2621/4885TARS1 299/4885ADORA3 3723/4885 |
| US-11939600-B2 | Compositions and methods for treating phenylketonuria | PAH, POLRMT, EGLN3 | ADORA1 3193/4885TARS1 1669/4885ADORA3 2838/4885 |
| US-20240002815-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, ODC1, OSGEP | ADORA1 1330/4885TARS1 247/4885ADORA3 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.